Last reviewed · How we verify
Rituximab (R)
Rituximab (R) is a CD20-targeting monoclonal antibody Small molecule drug developed by National Cancer Institute (NCI). It is currently FDA-approved for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis. Also known as: Rituxan, Rituximab, Induction phase, Truxima.
Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.
Rituximab is a medication used to treat various types of lymphoma and leukemia, including Large B-cell Lymphoma, Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Lymphoma, and Chronic Lymphocytic Leukemia. It is often used in combination with other medications, such as Prednisone and Cyclophosphamide, as part of a treatment regimen.
At a glance
| Generic name | Rituximab (R) |
|---|---|
| Also known as | Rituxan, Rituximab, Induction phase, Truxima |
| Sponsor | National Cancer Institute (NCI) |
| Drug class | CD20-targeting monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | FDA-approved |
Mechanism of action
Rituximab targets CD20, a surface antigen expressed on B lymphocytes. By binding to CD20, it triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B cell depletion. This mechanism is effective in B-cell malignancies and autoimmune diseases where B cells play a pathogenic role.
Approved indications
- Non-Hodgkin's lymphoma (B-cell)
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis
- Granulomatosis with polyangiitis (GPA)
- Microscopic polyangiitis (MPA)
Common side effects
- Infusion reactions
- Infections
- Cytopenias (anemia, thrombocytopenia, neutropenia)
- Fatigue
- Fever
- Tumor lysis syndrome
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL (PHASE2)
- Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma (PHASE2)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2, PHASE3)
- A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rituximab (R) CI brief — competitive landscape report
- Rituximab (R) updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI
Frequently asked questions about Rituximab (R)
What is Rituximab (R)?
How does Rituximab (R) work?
What is Rituximab (R) used for?
Who makes Rituximab (R)?
Is Rituximab (R) also known as anything else?
What drug class is Rituximab (R) in?
What development phase is Rituximab (R) in?
What are the side effects of Rituximab (R)?
What does Rituximab (R) target?
Related
- Drug class: All CD20-targeting monoclonal antibody drugs
- Target: All drugs targeting CD20
- Manufacturer: National Cancer Institute (NCI) — full pipeline
- Therapeutic area: All drugs in Oncology, Immunology
- Indication: Drugs for Non-Hodgkin's lymphoma (B-cell)
- Indication: Drugs for Chronic lymphocytic leukemia (CLL)
- Indication: Drugs for Rheumatoid arthritis
- Also known as: Rituxan, Rituximab, Induction phase, Truxima
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing